Cresset Asset Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $70.8M | Buy |
59,006
+7,017
| +13% | +$7.17M | 0.26% | 65 |
|
|
2026
Q1 | $47.8M | Sell |
51,989
-8,648
| -14% | -$8.77M | 0.21% | 78 |
|
|
2025
Q4 | $65.2M | Buy |
60,637
+411
| +0.7% | +$393K | 0.27% | 63 |
|
|
2025
Q3 | $46M | Sell |
60,226
-1,259
| -2% | -$937K | 0.2% | 75 |
|
|
2025
Q2 | $47.9M | Sell |
61,485
-6,198
| -9% | -$4.82M | 0.24% | 69 |
|
|
2025
Q1 | $55.9M | Sell |
67,683
-11,307
| -14% | -$9.41M | 0.28% | 57 |
|
|
2024
Q4 | $61M | Sell |
78,990
-54,144
| -41% | -$44.8M | 0.29% | 52 |
|
|
2024
Q3 | $118M | Buy |
133,134
+2,231
| +2% | +$2.01M | 0.45% | 33 |
|
|
2024
Q2 | $119M | Buy |
130,903
+30,044
| +30% | +$24M | 0.5% | 29 |
|
|
2024
Q1 | $78.5M | Buy |
100,859
+8,492
| +9% | +$6.04M | 0.38% | 39 |
|
|
2023
Q4 | $53.8M | Buy |
92,367
+6,101
| +7% | +$3.56M | 0.32% | 44 |
|
|
2023
Q3 | $46.3M | Sell |
86,266
-270
| -0.3% | -$139K | 0.18% | 62 |
|
|
2023
Q2 | $40.6M | Buy |
86,536
+51,504
| +147% | +$21.6M | 0.05% | 117 |
|
|
2023
Q1 | $12M | Sell |
35,032
-95,564
| -73% | -$32.2M | 0.24% | 72 |
|
|
2022
Q4 | $46.9M | Sell |
130,596
-10
| -0% | -$3.55K | 0.59% | 30 |
|
|
2022
Q3 | $42.2M | Buy |
130,606
+6,040
| +5% | +$1.91M | 0.53% | 26 |
|
|
2022
Q2 | $39.9M | Sell |
124,566
-2,517
| -2% | -$756K | 0.49% | 26 |
|
|
2022
Q1 | $36.4M | Sell |
127,083
-6,224
| -5% | -$1.6M | 0.38% | 33 |
|
|
2021
Q4 | $36.8M | Buy |
133,307
+7,332
| +6% | +$1.86M | 0.36% | 34 |
|
|
2021
Q3 | $29.1M | Sell |
125,975
-7,592
| -6% | -$1.87M | 0.39% | 27 |
|
|
2021
Q2 | $30.7M | Buy |
133,567
+7,315
| +6% | +$1.47M | 0.43% | 25 |
|
|
2021
Q1 | $23.6M | Buy |
126,252
+3,799
| +3% | +$743K | 0.37% | 29 |
|
|
2020
Q4 | $20.7M | Sell |
122,453
-4,559
| -4% | -$681K | 0.34% | 29 |
|
|
2020
Q3 | $18.8M | Buy |
127,012
+235
| +0.2% | +$36.4K | 0.35% | 28 |
|
|
2020
Q2 | $20.8M | Buy |
126,777
+11,946
| +10% | +$1.83M | 0.46% | 26 |
|
|
2020
Q1 | $15.9M | Buy |
114,831
+4,922
| +4% | +$676K | 0.48% | 26 |
|
|
2019
Q4 | $14.4M | Buy |
109,909
+1,128
| +1% | +$131K | 0.39% | 27 |
|
|
2019
Q3 | $12.2M | Buy |
108,781
+1,053
| +1% | +$117K | 0.37% | 31 |
|
|
2019
Q2 | $11.9M | Sell |
107,728
-9,814
| -8% | -$1.16M | 0.37% | 41 |
|
|
2019
Q1 | $15.3M | Buy |
117,542
+31,204
| +36% | +$3.79M | 0.59% | 18 |
|
|
2018
Q4 | $9.99M | Buy |
+86,338
| New | +$9.64M | 0.59% | 18 |
|
Other funds holding LLY
Cresset Asset Management's LLY Position: Q2 2026 in Review
Cresset Asset Management increased its Eli Lilly (LLY) stake by 13% in Q2 2026, buying an estimated $7.17M and bringing the position to 59,006 shares worth $70.8M. The position accounts for 0.26% of the portfolio, ranked #65.
Cresset Asset Management first reported a position in LLY in Q4 2018 and has held it in 31 quarters since. The position peaked at $119M in Q2 2024. 4,626 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Cresset Asset Management held 59,006 shares of Eli Lilly worth $70.8M as of Q2 2026.
- Cresset Asset Management bought 7,017 Eli Lilly shares in Q2 2026, an estimated $7.17M.
- Eli Lilly made up 0.26% of Cresset Asset Management's portfolio in Q2 2026, its #65 holding.
- Cresset Asset Management first reported a position in Eli Lilly in Q4 2018 and has held it in 31 quarters since.
- Cresset Asset Management's Eli Lilly position peaked at $119M in Q2 2024.
- 4,626 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.